• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification and analysis of tyrosine phosphatase CD45 interacting proteins

Research Project

Project/Area Number 09680653
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Biophysics
Research InstitutionKagoshima University

Principal Investigator

FURUKAWA Tatsuhiko  Faculty of Medicine, Kagoshima University Research Associate, 医学部, 助手 (40219100)

Co-Investigator(Kenkyū-buntansha) TANI Ayako  Faculty of Medicine, Kagoshima University Research Associate, 医学部, 助手 (70284867)
Project Period (FY) 1997 – 1998
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 1998: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1997: ¥2,400,000 (Direct Cost: ¥2,400,000)
Keywordstyrosine phosphatase / CD45 / T cell / CD3zeta / LAR / insulin receptor / CD35 / CD3 / LCK / ZAP70
Research Abstract

CD45 and leukocyte common antigen-related protein(LAR) have two tandem-repeated PTPase domains in the cytoplasmic segment like most of other transmembrane protein tyrosine phosphatases (RTPases). PTPase activity is associated only with the first of the two domains, PTPase domain 1(D1), and the membrane-distal PTPase domain 2(D2), which has no catalytic activity, would regulate substrate specificity.
From the lysate of co-expression of CD3zeta, lck and CD45D1CS, whose cystein at 828 has replaced with serine, phosphorylated CD3zeta was coprecipitated with CD45D1CS using anti-CD45 antibody. This finding indicates CD3zeta is a good substrate of CD45 also in vivo. Three kinds mutants MC1, MC2, MC3 of CD3zeta, which are carrying only 2 tyrosine residues, 2nd and 3rd, 1st and 3rd, 1st and 2nd tyrosine from C terminus, were made. All 3 mutants can be poorly phosphorylated with Ick and has almost same affinty with CD45D1CS, but SHC-SH2 can not bind with phosphorylated MC2 mutant.
CD45D1D2CS, whose cystein at 1144 was replaced with serine, has lower affinity with CD3zeta, and phsophorylated CD3zeta than CD45D1CS.Cystein of D2 has an important role of recognition of CD3zeta, independently of phosphorylation.
We studied on LAR and insuline receptor (IR) interaction also. LAR was associated with and preferentially dephosphorylated the insulin receptor which was tyrosine-phosphorylated after insulin stimulation. LARD1CS can bind phosphorylated IR stably. IR can be a phsiological substrate of LAR.LAR is phsophorylated with IRkinase after insuline stimulation. LARD1D2CS , whose cystein 1813 is changed to serine in the domain 2, has lower affinity with IR and higher phosphrylation than LARDICS.
These findings suggests LARD2 has auto-dephosphorylation activity. These data indicate that D1PTP of CD45 and LAR has main phosphatase activity and D2 PTP of them can recognize the substrates independently of phosphorylation.

Report

(3 results)
  • 1998 Annual Research Report   Final Research Report Summary
  • 1997 Annual Research Report
  • Research Products

    (38 results)

All Other

All Publications (38 results)

  • [Publications] Tomoyuki Sumizawa: "Reversal of MRP-associated drug resistance by the pyridine analog, PAK-104P" Mol.Pharmacol.51. 399-405 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kengo Nishimoto: "Thymidine phosphorylase activity required for tumor angiogenesis and growth." Oncology Reports. 4. 55-58 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yukihiro Nakamura: "Function of P-glycoprotein expressed in placeta and mole." Biochem.Biophys.Res.Commun.235. 849-853, (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Zhe-Sheng Chen: "Reversal of heavy metal resistance in multidrug resistant human KB carcinoma cells." Biochem.Biophys.Res.Commun.236. 586-590 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Zhe-Sheng Chen: "An active efflux system for heavy metal in cisplatin-resistant human KB carcinoma cells." Exp.Cell Res.240. 312-320 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yuki Takebayashi: "The expression of multidrug resistance protein(MRP)in human gastrointestinal tract carcinoma." Cancer. 82. 661-666 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yutaka Chuman: "Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximide in combination with PAK-104P" Cancer Lett.129. 69-76 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shu-ichi Nagayama: "Increased sensitivity to vincristine of MDR cells by the leukotrieneD4 receptor antagonist, ONO-1078." Cancer Lett.130. 175-182 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kitazono,M: "Prevention of hypoxia-induced apoptosis by the agiogenic factor thymidine phosphorylase." Biochem.Biophys.Res.Commun.253. 797-803 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Chen, Z.S.: "An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells." Cancer Lett.(in press). (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Matsushita,S: "The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors." Cancer Res.(in press). (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Tomoyuki Sumizawa, Zhen-Sheng Chen, Yutaka Chuman, Kiyotomo Seto, Tatsuhiko Furukawa, Misako Haraguchi, Ayako Tani, Norimasa Shudo, and Shin-ichi Akiyama: "Reversal of MRP-associated drug resistance by the pyridine analog, PAK-104P." Mol.Pharmacol.51. 399-405 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kengo Nishimoto, Kazutaka Miyadera, Yuji Takebayashi, Katsunori Fukuda, Misako Haraguchi, Tatsuhiko Furukawa, Yuji Yamada and Shin-ichi Akiyama: "Thymidine phosporylase activity required for tumor angiogenesis and growth." Oncology Reports. 4. 55-58 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yukihiro Nakamura, Shun-ichi Ikeda, Tatsuhiko Furukawa, Tomoyuki Sumizawa, Ayako Tani, Shin-ichi Akiyama, and Yukihiro Nagata: "Function of P-glycoprotein expressed in placeta and mole." Biochem.Biophys.Res.Commun.235. 849-853 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Zhe-Sheng Chen, Masato Mutoh, Tomoyuki Sumizawa, Tatsuhiko Furukawa, Misako Haraguchi, Ayako Tani, and Shin-ichi Akiyama: "Reversal of heavy metal resistance in multidrug resistant human KB carcinoma cells." Biochem.Biophys.Res.Commun.236. 586-590 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Zhe-Sheng Chen, Masato Mutoh, Tomoyuki Sumizawa, Tatsuhiko Furukawa, Misako Haraguchi, Ayako Tani, Nagahiro Saijo, Takahito Kondo, and Shin-ichi Akiyama: "An active efflux system for heavy metal in cisplatin-resistant human KB carcinoma cells." Exp.Cell Res.240. 312-320 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yuji Takebayashi, Shin-ichi Akiyama, Shoji Natsugoe, Shuichi Hokita, Kiyoshi Niwa, Masaki Kitazono, Tomoyuki Sumizawa, Misako Haraguchi, Tatsuhiko Furukawa, Shuichi Nagayama and Takeshi Aikou: "The expression of multidrug resistance protein (MRP) in human gastrointestinal tract carcinoma." Cancer. 82. 661-666 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yutaka Chuman, Zhen-Sheng Chen, Kiyotomo Seto, Tomoyuki Sumizawa, Tatsuhiko Furukawa, Ayako Tani, Misako Haraguchi, Kiyoshi Niwa, Kazutaka Yamada, Takashi Aikou and Shin-ichi Akiyama: "Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximide in combination with PAK-104P." Cancer.Lett.129. 69-76 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Shu-ichi Nagayama, Zhen-Sheng Chen, Masaki Kitazono, Yuji Takebayashi, Kiyoshi Niwa, Kazutaka Yamada, Ayako Tani, Misako Haraguchi, Tomoyuki Sumizawa, Tatsuhiko Furukawa, Takashi Aikou and Shin-ichi Akiyama: "Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078." Cancer Lett.130. 175-182 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Kitazono, M., Takebayashi, Y., Ishitsuka, K., Takao, S., Tani, A., Furukawa, T., Miyadera, K., Yamada, Y., Aikou, T.and Akiyama, S.: "Prevention of hypoxia-induced apoptosis by the agiogenic factor thymidine phosphorylase." Biochem.Biophys.Res.Commun.253. 797-803 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Chen, Z.S., Sumizawa, T., Furukawa, T., Ono, K., Tani, A., Komatsu, M.and Akiyama, S.: "An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells." Cancer Lett.(in press). (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Matsushita, S., Nitanda, T., Furukawa, T., Sumizawa, T., Tani, A., Nishimoto, K., Akiba, S., Miyadera, K., Fukushima, M., Yamada, Y., Yoshida, H., Kanzaki, T.and Akiyama, S.: "The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors." Cancer Res.(in press). (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Tomoyuki Sumizawa: "Reversal of MRP-associated drug resistance by the pyridine analog,PAK-104P." Mol.Pharmacol.51. 399-405 (1997)

    • Related Report
      1998 Annual Research Report
  • [Publications] Kengo Nishimoto: "Thymidine phosporylase activity required for tumor angiogenesis and growth." Oncology Reports. 4. 55-58 (1997)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yukihiro Nakamura: "Function of P-glycoprotein expressed in Placeta and mole." Biochem.Biophys.Res.Commun.235. 849-853 (1997)

    • Related Report
      1998 Annual Research Report
  • [Publications] Zhe-Sheng Chen: "Reversal of heavy metal resistance in multidrug resistant human KB carcinoma cells." Biochem.Biophys.Res.Commun.236. 586-590 (1997)

    • Related Report
      1998 Annual Research Report
  • [Publications] Zhe-Sheng Chen: "An active efflux system for heavy metal in cisplatin-resisitant human KB carcinoma cells." Exp.Cell Res.240. 312-320 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yuji Takebayashi: "The expression of multidrug resistance protein(MRP)in human gastrointestinal tract carcinoma." Cancer. 82. 661-666 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yutaka Chuman: "Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximide in combination with PAK-104P." Can.Lett.129. 69-76 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Shu-ichi Nagayama: "Increased sensitivity to vincristine of MDR cells by the leukotrieneD4 receptor antagonist,ONO-1078." Can.Lett.130. 175-182 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Kitazono,M: "Prevention of hypoxia-induced apoptosis by the agiogenic factor thymidine phosphorylase." Biochem.Biophys.Res.Commun.253. 797-803 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Chen,Z.S.: "An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells." Cancer.Lett.(in press). (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Matsushita,S: "The effect of a thymidine phosphorylase inhibitor on angiogenesis and apotosis in tumors." Cancer Res.(in press). (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Tomoyuki Sumizawa: "Reversal of MRP-associated drug resistance by the pyridine analog,PAK-104P" Molecular Pharmacology. 51. 399-405 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Yukihiro Nakamura: "Function of P-glycoprotein expressed in placenta and mole" Biochemical and Biophysical Research Communications. 235. 849-853 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Zhe-Sheng Chen: "Reversal of heavy metal resistance in multidrug resistant human KBcaricinoma cells" Biochemical and Biophysical Research Communications. 236. 586-590 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Kengo Nishimoto: "Thymidine phosphorylase activity required for tumor angiogenesis and growth" Oncology Report. 4. 55-58 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Zhe-Sheng Chen: "An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells" Experimental Cell Research. (発表予定). (1998)

    • Related Report
      1997 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi